吸入莫格司亭治疗自身免疫性肺泡蛋白沉积症的3期试验
本项目为3期双盲安慰剂对照试验,纳入164例自身免疫性肺泡蛋白沉积症患者,随机接受吸入莫格司亭300 μg或安慰剂每日一次,共48周。主要终点为基线至第24周DLCO(经血红蛋白校正,占预计值百分比)变化。莫格司亭组第24周DLCO最小二乘均值升高9.8个百分点(95%CI 7.3–12.3),安慰剂组升高3.8个百分点(95%CI 1.4–6.3),估计治疗差6.0个百分点(95%CI 2.5–9.4,P<0.001)。第48周DLCO变化分别为11.6(95%CI 8.7–14.5)和4.7(95%CI 1.8–7.6)个百分点(P<0.001);第24周SGRQ-T评分变化分别为-11.5(95%CI -15.0至-8.0)和-4.9(95%CI -8.3至-1.5)分(P=0.007)。第24周SGRQ-A评分组间无显著差异,故后续次要终点未做统计推断。两组至少发生一次不良事件和至少发生一次严重不良事件的患者百分比相似。
要点
- 自身免疫性肺泡蛋白沉积症患者每日一次吸入莫格司亭300 μg,第24周DLCO较基线升高9.8个百分点,安慰剂组升高3.8个百分点,治疗差6.0个百分点(95%CI 2.5–9.4,P<0.001)。
- 第48周DLCO变化莫格司亭组11.6个百分点(95%CI 8.7–14.5),安慰剂组4.7个百分点(95%CI 1.8–7.6),P<0.001。
- 第24周SGRQ-T评分变化莫格司亭组-11.5分(95%CI -15.0至-8.0),安慰剂组-4.9分(95%CI -8.3至-1.5),P=0.007。
- 第24周SGRQ-A评分组间无显著差异,后续次要终点未做统计推断。
- 两组至少一次不良事件和至少一次严重不良事件的患者百分比相似。
适用人群与场景
- 自身免疫性肺泡蛋白沉积症患者,随机分组共164例,其中莫格司亭组81例、安慰剂组83例。
处置流程与药物剂量
- 莫格司亭300 μg吸入,每日一次,疗程48周。
研究设计与关键结果
- 3期双盲安慰剂对照试验,164例自身免疫性肺泡蛋白沉积症患者随机接受吸入莫格司亭300 μg(81例)或安慰剂(83例)每日一次,共48周。
- 主要终点基线至第24周DLCO(经血红蛋白校正,占预计值百分比)最小二乘均值变化:莫格司亭组9.8个百分点(95%CI 7.3–12.3),安慰剂组3.8个百分点(95%CI 1.4–6.3),估计治疗差6.0个百分点(95%CI 2.5–9.4,P<0.001)。
- 第48周DLCO最小二乘均值变化:莫格司亭组11.6个百分点(95%CI 8.7–14.5),安慰剂组4.7个百分点(95%CI 1.8–7.6),P<0.001。
- 第24周SGRQ-T评分最小二乘均值变化:莫格司亭组-11.5分(95%CI -15.0至-8.0),安慰剂组-4.9分(95%CI -8.3至-1.5),P=0.007。
- 第24周SGRQ-A评分组间无显著差异,故后续次要终点未做统计推断。
- 两组至少发生一次不良事件和至少发生一次严重不良事件的患者百分比相似。
证据类型、等级与局限
- 证据类型:3期双盲安慰剂对照随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,每日一次吸入莫格司亭可使自身免疫性肺泡蛋白沉积症患者肺气体交换较安慰剂更明显改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), which alveolar macrophages require to clear surfactant. Molgramostim is a formulation of inhaled recombinant human GM-CSF, but its efficacy and safety in patients with aPAP have not been studied sufficiently.
METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with aPAP to receive molgramostim at a dose of 300 μg or placebo once daily for 48 weeks. The primary end point was the change from baseline to week 24 in the diffusing capacity of the lungs for carbon monoxide (DLCO), which was adjusted for hemoglobin concentration and expressed as a percentage of the predicted value. Secondary end points adjusted for multiplicity were the change from baseline in DLCO at 48 weeks and the change from baseline in the St. George's Respiratory Questionnaire total (SGRQ-T) and activity (SGRQ-A) scores (scores range from 0 to 100, with lower scores indicating better quality of life) and in exercise capacity at 24 and 48 weeks.
RESULTS: A total of 164 patients underwent randomization: 81 were assigned to receive molgramostim and 83 to receive placebo. The least-squares mean change in DLCO from baseline to week 24 was 9.8 percentage points (95% confidence interval [CI], 7.3 to 12.3) with molgramostim and 3.8 percentage points (95% CI, 1.4 to 6.3) with placebo (estimated treatment difference, 6.0 percentage points; 95% CI, 2.5 to 9.4; P<0.001). The least-squares mean change in DLCO from baseline to week 48 was 11.6 percentage points (95% CI, 8.7 to 14.5) with molgramostim and 4.7 percentage points (95% CI, 1.8 to 7.6) with placebo (P<0.001), and the least-squares mean change in the SGRQ-T score at week 24 was -11.5 points (95% CI, -15.0 to -8.0) and -4.9 points (95% CI, -8.3 to -1.5), respectively (P = 0.007). No significant between-group difference in the change in SGRQ-A score was observed at 24 weeks, so no statistical inference was drawn with respect to subsequent secondary end points. The percentage of patients with at least one adverse event and the percentage with at least one serious adverse event were similar in the two groups.
CONCLUSIONS: Once-daily inhaled molgramostim led to a greater increase in pulmonary gas transfer than placebo in patients with aPAP. (Funded by Savara; IMPALA-2 ClinicalTrials.gov number, NCT04544293; European Union Clinical Trials Information System number, 2024-511052-41-00.).
参考来源
- Trapnell BC, Inoue Y, Bonella F, et al. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med. 2025. PMID: 40834301. doi:10.1056/NEJMoa2410542
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。